178 lines
40 KiB
HTML
178 lines
40 KiB
HTML
<!DOCTYPE html>
|
||
<html lang="" xml:lang="" xmlns="http://www.w3.org/1999/xhtml"><head>
|
||
<meta charset="utf-8"/>
|
||
<meta content="pandoc" name="generator"/>
|
||
<meta content="width=device-width, initial-scale=1.0, user-scalable=yes" name="viewport"/>
|
||
<title>13 December, 2022</title>
|
||
<style>
|
||
code{white-space: pre-wrap;}
|
||
span.smallcaps{font-variant: small-caps;}
|
||
span.underline{text-decoration: underline;}
|
||
div.column{display: inline-block; vertical-align: top; width: 50%;}
|
||
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
|
||
ul.task-list{list-style: none;}
|
||
</style>
|
||
<title>Covid-19 Sentry</title><meta content="width=device-width, initial-scale=1.0" name="viewport"/><link href="styles/simple.css" rel="stylesheet"/><link href="../styles/simple.css" rel="stylesheet"/><link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet"/><script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script></head>
|
||
<body>
|
||
<h1 data-aos="fade-down" id="covid-19-sentry">Covid-19 Sentry</h1>
|
||
<h1 data-aos="fade-right" data-aos-anchor-placement="top-bottom" id="contents">Contents</h1>
|
||
<ul>
|
||
<li><a href="#from-preprints">From Preprints</a></li>
|
||
<li><a href="#from-clinical-trials">From Clinical Trials</a></li>
|
||
<li><a href="#from-pubmed">From PubMed</a></li>
|
||
<li><a href="#from-patent-search">From Patent Search</a></li>
|
||
</ul>
|
||
<h1 data-aos="fade-right" id="from-preprints">From Preprints</h1>
|
||
<ul>
|
||
<li><strong>Immunogenic fusion proteins induce neutralizing SARS-CoV-2 antibodies in the serum and milk of sheep</strong> -
|
||
<div>
|
||
Antigen-specific polyclonal immunoglobulins derived from the serum, colostrum, or milk of immunized ruminant animals have potential as scalable therapeutics for the control of viral diseases such as COVID-19. Enhancing the efficacy of vaccine antigens to induce robust and specific antibody responses remains central to developing highly effective formulations. The direct fusion of immunoglobulin (IgG) Fc domains or other immune-stimulating proteins to antigens has shown promise in several mammalian species but has not yet been tested and optimized in commercially-relevant ruminant species. Here we show that the immunization of sheep with fusions of the receptor binding domain (RBD) of SARS-CoV-2 to ovine IgG2a Fc domains promotes significantly higher levels of antigen-specific antibodies compared to native RBD or full-length spike antigens. This antibody population was shown to contain elevated levels of neutralizing antibodies that suppress binding between the RBD and soluble hACE2 receptors in vitro. The parallel evaluation of a second immune-stimulating fusion candidate, Granulocyte-macrophage colony-stimulating factor (GM-CSF), induced high neutralizing responses in select animals but narrowly missed achieving significance at the group level. Furthermore, we demonstrate that the antibodies induced by these fusion antigens are transferred from maternal serum into colostrum/milk. These antibodies also demonstrate cross-neutralizing activity against diverse SARS-CoV-2 variants including delta and omicron. Our findings highlight a new pathway for recombinant antigen design in ruminant animals with applications in immune milk production and animal health.
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2022.12.11.519990v1" target="_blank">Immunogenic fusion proteins induce neutralizing SARS-CoV-2 antibodies in the serum and milk of sheep</a>
|
||
</div></li>
|
||
<li><strong>Identification of genomic signatures and multiple lineage markers from the second and third wave samples of COVID-19 in Western Rajasthan, India</strong> -
|
||
<div>
|
||
Most of the mutations occurred in SARS-CoV-2 are either relatively neutral or swiftly purged. However, some mutations have altered the functional aspects in terms of infectivity and transmission, host-viral interactions, disease severity and immune or vaccine escape. There are emerging evidence that certain mutations are jeopardizing the immune based therapies. The present research report is focused on the identification of genomic signatures of SARS-CoV-2 variant that caused mortality during second and third wave of COVID-19 in Western Rajasthan, India. We identified that Delta clade of SARS-CoV-2 is the predominant cause of mortality during second wave and even third wave in Western Rajasthan, India. Importantly, this study also revealed the unique and common substitution mutations within the spike domain, those are present in mortality and survived persons during the second and third wave of COVID-19 in India. In addition, this study also revealed the multiple lineage markers (Delta and Omicron), that would update with insightful understanding in the clade development of SARS-CoV-2.
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2022.12.10.518819v1" target="_blank">Identification of genomic signatures and multiple lineage markers from the second and third wave samples of COVID-19 in Western Rajasthan, India</a>
|
||
</div></li>
|
||
<li><strong>Using machine learning to detect coronaviruses potentially infectious to humans</strong> -
|
||
<div>
|
||
Establishing the host range for novel viruses remains a challenge. Here, we address the challenge of identifying non-human animal coronaviruses that may infect humans by creating an artificial neural network model that learns from the binding of the spike protein of alpha and beta coronaviruses to their host receptor. The proposed method produces a human-Binding Potential (h-BiP) score that distinguishes, with high accuracy, the binding potential among human coronaviruses. Two viruses, previously unknown to bind human receptors, were identified: Bat coronavirus BtCoV/133/2005 (a MERS related virus) and Rhinolophus affinis coronavirus isolate LYRa3 a SARS related virus. We further analyze the binding properties of these viruses using molecular dynamics. To test whether this model can be used for surveillance of novel coronaviruses, we re-trained the model on a set that excludes SARS-COV-2 viral sequences. The results predict the binding of SARS-CoV-2 with a human receptor, indicating that machine learning methods are an excellent tool for the prediction of host expansion events.
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2022.12.11.520008v1" target="_blank">Using machine learning to detect coronaviruses potentially infectious to humans</a>
|
||
</div></li>
|
||
<li><strong>Dynamical nonequilibrium molecular dynamics simulations identify allosteric sites and positions associated with drug resistance in the SARS-CoV-2 main protease</strong> -
|
||
<div>
|
||
The SARS-CoV-2 main protease (Mpro) plays an essential role in the coronavirus lifecycle by catalysing hydrolysis of the viral polyproteins at specific sites. Mpro is the target of drugs, such as nirmatrelvir, though resistant mutants have emerged that threaten drug efficacy. Despite its importance, questions remain on the mechanism of how Mpro binds its substrates. Here, we apply dynamical nonequilibrium molecular dynamics (D-NEMD) simulations to evaluate structural and dynamical responses of Mpro to the presence and absence of a substrate. The results highlight communication between the Mpro dimer subunits and identify networks, including some far from the active site, that link the active site with a known allosteric inhibition site, or which are associated with nirmatrelvir resistance. They imply that some mutations enable resistance by altering the allosteric behaviour of Mpro. More generally, the results show the utility of the D-NEMD technique for identifying functionally relevant allosteric sites and networks including those relevant to resistance.
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2022.12.10.519730v1" target="_blank">Dynamical nonequilibrium molecular dynamics simulations identify allosteric sites and positions associated with drug resistance in the SARS-CoV-2 main protease</a>
|
||
</div></li>
|
||
<li><strong>Estimating Subnation Excess Mortality in Times of Pandemic. An application to French Departements in 2020.</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
The Covid-19 pandemic did not affect sub-national regions in a uniform way. Knowledge of the impact of the pandemic on mortality at the local level is therefore an important issue for better assessing its burden. Vital statistics are now available for an increasing number of countries for 2020 and 2021 and allow the calculation of sub-national excess mortality. However, this calculation faces two important methodological challenges: (1) it requires appropriate mortality projection models; (2) small populations imply important uncertainty in the estimates, commonly neglected. We address both issues by adopting a method to forecast mortality at sub-national level and by incorporating uncertainty in the computation of mortality measures. We illustrate our approach to French departements (NUTS 3, 95 geographical units) and produce estimates for 2020 and both sexes. Nonetheless, the proposed approach is so flexibility to allow estimation of excess mortality during Covid-19 in most demographic scenarios as well as for past pandemics.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.12.12.22283346v1" target="_blank">Estimating Subnation Excess Mortality in Times of Pandemic. An application to French Departements in 2020.</a>
|
||
</div></li>
|
||
<li><strong>Machine learning identifies a COVID-19-specific phenotype in university students using a mental health app</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
Advances in smartphone technology have allowed people to access mental healthcare via digital apps from wherever and whenever they choose. University students experience a high burden of mental health concerns. Although these apps improve mental health symptoms, user engagement has remained low. Studies have shown that users can be subgrouped based on unique characteristics that just-in-time adaptive interventions (JITAIs) can use to improve engagement. To date, however, no studies have examined the effect of the COVID-19 pandemic on these subgroups. Here, we use machine learning to examine user subgroup characteristics across three COVID-19-specific timepoints: during lockdown, immediately following lockdown, and three months after lockdown ended. We demonstrate that there are three unique subgroups of university students who access mental health apps. Two of these, with either higher or lower mental well-being, were defined by characteristics that were stable across COVID-19 timepoints. The third, situational well-being, had characteristics that were timepoint-dependent, suggesting that they are highly influenced by traumatic stressors and stressful situations. This subgroup also showed feelings and behaviours consistent with burnout. Overall, our findings clearly suggest that user subgroups are unique: they have different characteristics and therefore likely have different mental healthcare goals. Our findings also highlight the importance of including questions and additional interventions targeting traumatic stress(ors), reason(s) for use, and burnout in JITAI-style mental health apps to improve engagement.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.12.07.22283234v1" target="_blank">Machine learning identifies a COVID-19-specific phenotype in university students using a mental health app</a>
|
||
</div></li>
|
||
<li><strong>The protection gap under a social health protection initiative in the COVID-19 pandemic: A case study from Khyber Pakhtunkhwa, Pakistan.</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
Background Sehat Sahulat Programme (SSP) is a Social Health Protection (SHP) initiative by the Government of Khyber Pakhtunkhwa (GoKP), covering inpatient services for 100% of the province’s population. In this paper, we describe SSP’s role in GoKP’s COVID-19 response and draw inferences for similar programmes in Pakistan. Methodology and methods We conceptualised SSP as an instrumental case study and collected three complementary data sources. First, we studied GoKP’s official documents to understand SSP’s benefits package. Then we undertook in-depth interviews and collected non-participant observations at the SSP policy and implementation levels. We recruited participants through direct (verbal and email) and indirect (invitation posters) methods. Use of maximum variation sampling enabled us to understand contrasting views from various stakeholders on SSP’s policy dimensions (i.e., coverage and financing), tensions between the policy directions (i.e., whether or not to cover COVID-19) and how policy decisions were made and implemented. We collected data from March 2021 to December 2021. Thematic analysis was conducted with the help of Nvivo12. Findings Throughout 2020, SSP did not cover COVID-19 treatment. The insurer and GoKP officials considered the pandemic a standard exclusion to insurance coverage. One SSP official said: “COVID-19 is not covered and not relevant to us”. GoKP had stopped non-emergency services at all hospitals. When routine services restarted, the insurer did not cover COVID-19 screening tests, which were mandatory prior to hospital admission. In 2021, GoKP engaged 10 private SSP hospitals for COVID-19 treatment. The SSP Reserve Fund, rather than insurance pooled money, was used. The Reserve Fund was originally meant to cover high-cost organ transplants. In 2021, SSP had 1,002 COVID-19-related admissions, which represented 0.2% of all hospital admissions (N=544,841). An advocacy group representative called the COVID-19 care under SSP “too little too late”. In contrast, SSP officials suggested their insurance database and funds flow mechanism could help GoKP in future health emergencies. Conclusion The commercially focused interpretation of SHP arrangements led to a protection gap in the context of COVID-19. SSP and similar programmes in other provinces of Pakistan should emphasise the notion of protection and not let commercial interests lead to protection gaps.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.11.29.22282883v1" target="_blank">The protection gap under a social health protection initiative in the COVID-19 pandemic: A case study from Khyber Pakhtunkhwa, Pakistan.</a>
|
||
</div></li>
|
||
<li><strong>Pharmacognosy and Phytochemistry: Bridging the Knowledge Gaps for the LMICs (A Mobile App Review)</strong> -
|
||
<div>
|
||
This study reiterates further on the educational needs for plant derivatives as a source for Nutritional / Pharmaceutical (Nutraceutical, Cosmetics and endless) products in our ever-changing world of Research and Development (R&D). The study is focused mainly on the Lower and Middle Income Countries (LMICs) peculiarities, in terms of how mobile applications (APPs) has influenced access to the pharmaceutical knowledge databases, taking work and life into consideration for synchronous & asynchronous online learning experiences. Not disregarding the fact that the Pedagogical methods tends to appeal more to the technical hands-on (practical) skill learners, especially in the field (s) of Pharmacognosy and Phytochemistry that involves a lengthy logistic moving rounds, coupled with staffing issues. Be that as it may, whoever oversees food and medicine in between the farm and the supermarket shelf deserves to be adequately trained. Uni (app) in pockets of health care personnel for Standard Operating Procedures (SOP)around Activities of Daily Living (ADL) is for the healthier world. Results: Today, unlike days before the COVID-19 Pandemic, almost all tutors and trainees of Life Sciences agreed that the online module tutored and assessed through ‘Mobile Applications’ was useful for new topic learning and revising, provided relevant content (and flexibility), and thus facilitated their understanding. Conclusion: The study concluded that the results obtained can be used to inform policymakers, educational institutions, mobile app developers and stakeholders for policy adjustment, incentives, skills updates and universal internet coverage for the LMICs, thereby promoting Universal Health Coverage (UHC), as well as food sustainability, while at the same time substantiating a much-needed restructuring to the pedagogical methods, of importance to the practical and intuition in Pharmaceutical education.
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://osf.io/syt3x/" target="_blank">Pharmacognosy and Phytochemistry: Bridging the Knowledge Gaps for the LMICs (A Mobile App Review)</a>
|
||
</div></li>
|
||
<li><strong>Regional personality differences predict variation in COVID-19 infections and social distancing behavior</strong> -
|
||
<div>
|
||
The early stages of the COVID-19 pandemic revealed stark regional variation in the spread of the virus. Combining self-reported personality data (3.5M people) with COVID-19 prevalence rates and behavioral mobility observations (29M people) in the US and Germany, we show that regional personality differences can help explain the early transmission of COVID-19; this is true even after controlling for a wide array of important socio-demographic, economic, and pandemic-related factors. We use specification curve analyses to test the effects of regional personality in a robust and unbiased way. The results indicate that in the early stages of COVID-19, Openness-to-experience acted as a risk factor while Neuroticism acted as a protective factor. The findings also highlight the complexity of the pandemic by showing that the effects of regional personality can differ (i) across countries (Extraversion), (ii) over time (Openness) and (iii) from those previously observed at the individual level (Agreeableness and Conscientiousness).
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://psyarxiv.com/sqh98/" target="_blank">Regional personality differences predict variation in COVID-19 infections and social distancing behavior</a>
|
||
</div></li>
|
||
<li><strong>Social bonds are related to health behaviours and positive wellbeing globally</strong> -
|
||
<div>
|
||
At times of turmoil – such as during natural disasters, social crises, or pandemics – our social bonds can be key to receiving support and gaining certainty about the right course of action. In an analysis combining two global datasets (N= 13,264) collected during the first wave of the COVID-19 pandemic, this study examined how social bonds with close social circles (i.e., family, friends) and extended groups (i.e., country, government, humanity) relate to engagement in health behaviours and psychological wellbeing. Results revealed that only family bonding was associated with self-reported engagement in health behaviours. Being strongly bonded with both close circles and extended groups predicted less anxiety and depression, and better wellbeing, particularly for those who were bonded with more groups. These findings highlight that close and extended social bonds offer different sources of support and direction during the most challenging of circumstances, and that continuous investment is needed to forge and maintain both.
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://psyarxiv.com/r7pd2/" target="_blank">Social bonds are related to health behaviours and positive wellbeing globally</a>
|
||
</div></li>
|
||
<li><strong>Psychological distance to science as a predictor of science skepticism across domains</strong> -
|
||
<div>
|
||
The current paper presents and tests psychological distance to science (PSYDISC) as a domain-general predictor of science skepticism. Drawing on the concept of psychological distance, PSYDISC reflects the extent to which individuals perceive science as a tangible undertaking conducted by people similar to oneself (social), with effects in the here (spatial) and now (temporal), and as useful and applicable in the real world (hypothetical distance). In six studies (2 preregistered; total N = 1,630) and two countries, we developed and established the factor structure and validity of a scale measuring PSYDISC. Crucially, higher PSYDISC predicted skepticism beyond established predictors, across science domains. A final study showed that PSYDISC shapes real-world behavior (COVID-19 vaccination uptake). The current work thus provides a novel tool to predict science skepticism, as well as a construct that can help to further develop a unifying framework to understand science skepticism across domains.
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://psyarxiv.com/avtgu/" target="_blank">Psychological distance to science as a predictor of science skepticism across domains</a>
|
||
</div></li>
|
||
<li><strong>Clomipramine inhibits dynamin GTPase activity by L-α-phosphatidyl-L-serine stimulation</strong> -
|
||
<div>
|
||
Three dynamin isoforms play critical roles in clathrin-dependent endocytosis. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enters host cells via clathrin-dependent endocytosis. We previously reported that 3-(9-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine (clomipramine) inhibits the GTPase activity of dynamin 1, which is in mainly neuron. Therefore, we investigated whether clomipramine inhibits the activity of other dynamin isoforms in this study. We found that, similar to its inhibitory effect on dynamin 1, clomipramine inhibited the L–phosphatidyl-L-serine-stimulated GTPase activity of dynamin 2, which is expressed ubiquitously, and dynamin 3, which is expressed in the lung. Inhibition of GTPase activity raises the possibility that clomipramine can suppress SARS-CoV-2 entry into host cells.
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2022.09.09.507370v3" target="_blank">Clomipramine inhibits dynamin GTPase activity by L-α-phosphatidyl-L-serine stimulation</a>
|
||
</div></li>
|
||
<li><strong>Posttraumatic stress disorder symptom trajectories in a 16-month COVID-19 pandemic period</strong> -
|
||
<div>
|
||
In the aftermath of mass trauma, posttraumatic stress disorder (PTSD) symptoms follow prototypical trajectories of resilience, recovery, or chronic distress. The coronavirus disease 2019 (COVID-19) pandemic represented an unheralded opportunity to better understand heterogeneous trajectories of PTSD symptoms across a prolonged period of social disruption and stress. We tracked the PTSD symptoms of trauma-exposed individuals in the U.S., sought to identify population-based variability in PTSD symptom trajectories, and understand what, if any, early pandemic experiences would predict their membership in one trajectory over others. As part of a large-scale longitudinal study of U.S. residents during the pandemic, participants who reported at least one potentially traumatic event in their lifetime (N = 1206) at Wave 1 (April 2020) were included in the current study. PTSD symptoms were assessed with the PTSD Checklist for DSM-5 at four time points extending to July 2021. Latent growth mixture modeling was used to identify heterogeneous symptom trajectories. Trajectory membership was regressed on baseline demographics and experiences from the early stage of the pandemic as measured by the Epidemic-Pandemic Impacts Inventory. Four trajectories (Resilient [73%], Recurring [13.3%], Recovering [8.3%], and Chronic [5.5%] were identified. Age, trauma load, and early pandemic experiences (emotional/physical health problems and positive changes) were each significant predictors of trajectory membership. Predictors primarily differentiated the Resilient from each of the other three trajectories. Distinct PTSD symptom trajectories during the COVID-19 pandemic point to the need for targeted efforts helping those at most risk for ongoing distress.
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://psyarxiv.com/wpjgm/" target="_blank">Posttraumatic stress disorder symptom trajectories in a 16-month COVID-19 pandemic period</a>
|
||
</div></li>
|
||
<li><strong>Visualization of early RNA replication kinetics of SARS-CoV-2 by using single molecule RNA-FISH</strong> -
|
||
<div>
|
||
SARS-CoV-2 infection has caused a major global burden. Despite intensive research, the mechanism and dynamics of early viral replication are not completely understood including the kinetics of formation of plus stranded genomic and subgenomic RNAs (gRNA and sgRNA) starting from the RNA from the first virus that enters the cell. We employed single-molecule RNA-fluorescence in situ hybridization (smRNA-FISH) to simultaneously detect viral gRNA and sgRNA in infected cells and carried out a time course analysis to determine the kinetics of their replication. We visualized the single molecules of gRNA within the cytoplasm of infected cells 30 minutes post-infection and detected the co-expression of gRNA and sgRNA within two hours post-infection. Furthermore, we observed the formation of a replication organelle (RO) from a single RNA, which led to the formation of multiple ROs within the same cells. Single molecule analysis indicated that while gRNA resided in the center of these ROs, the sgRNAs were found to radiate and migrate out of these structures. Our results also indicated that after the initial delay, there was a rapid but asynchronous replication, and the gRNA and sgRNAs dispersed throughout the cell within 4-5 hours post-infection forming multiple ROs that filled the entire cytoplasm. These results provide insight into the kinetics of early post-entry events of SARS-CoV-2 and the formation of RO, which will help to understand the molecular events associated with viral infection and facilitate the identification of new therapeutic targets that can curb the virus at a very early stage of replication to combat COVID-19.
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2022.12.10.517707v1" target="_blank">Visualization of early RNA replication kinetics of SARS-CoV-2 by using single molecule RNA-FISH</a>
|
||
</div></li>
|
||
<li><strong>Exploring B and T-cell epitopes for constructing a Novel Multiepitope vaccine to combat emerging Monkeypox infection: A Reverse Vaccinology approach</strong> -
|
||
<div>
|
||
Background: While the whole mankind is resurrecting from the recent Covid-19 pandemic, new cases of the monkeypox virus have been reported inflicting serious threats to the public health. Monkeypox is a newly emerging, zoonotic orthopoxvirus having similar symptoms as that of the smallpox. So far, no approved treatment and therapeutics are in line to fight the infection. Methodology: Therefore, in the present study, we have deployed a computational pipeline. We have retrieved the helper T-cell lymphocytes, cytotoxic T-cell and B-cell inducing epitopes by targeting the cell surface binding protein of the virus and further filtered the high-quality peptides based on their immunogenicity, antigenicity and allergenicity. After subsequent steps, we constructed and validated the tertiary structure of vaccine and analyzed its molecular interactions with toll like receptor-2 (TLR-2) and toll like receptor-4 (TLR-4) through molecular docking and the atomic movements and stability through molecular dynamics simulation approach. Moreover, C-IMMSIM server was used to evaluate the immune response triggering capacity of the chimeric vaccine through the immunoglobin profile. Conclusion: The conducted in silico study concludes that the surface protein of monkeypox virus is one of the major culprit antigens in mediating the disease. Hence, our study will aid in the better formulation of vaccines in future by targeting the suitable drug or vaccine candidates.
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2022.12.09.519581v1" target="_blank">Exploring B and T-cell epitopes for constructing a Novel Multiepitope vaccine to combat emerging Monkeypox infection: A Reverse Vaccinology approach</a>
|
||
</div></li>
|
||
</ul>
|
||
<h1 data-aos="fade-right" id="from-clinical-trials">From Clinical Trials</h1>
|
||
<ul>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Pilot Clinical Trial to Explore Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients</strong> - <b>Condition</b>: COVID-19<br/><b>Intervention</b>: Drug: Pyramax<br/><b>Sponsor</b>: Shin Poong Pharmaceutical Co. Ltd.<br/><b>Completed</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Animation Supported COVID-19 Education</strong> - <b>Condition</b>: COVID-19 Pandemic<br/><b>Intervention</b>: Other: Animation-Supported Education<br/><b>Sponsor</b>: Siirt University<br/><b>Completed</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>CareSuperb COVID-19 Antigen Test Usability</strong> - <b>Condition</b>: COVID-19<br/><b>Intervention</b>: Device: CareSuperb COVID-19 Antigen Home Test Kit<br/><b>Sponsor</b>: AccessBio, Inc.<br/><b>Recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>COVID-19 Huashi Baidu Formula Clinical Study</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Drug: Huashi Baidu Granule; Drug: Monapiravir<br/><b>Sponsors</b>: Xiyuan Hospital of China Academy of Chinese Medical Sciences; Beijing YouAn Hospital; Kossamak Hospital; Kamuzu University of Health Sciences<br/><b>Not yet recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Shaping Care Home COVID-19 Testing Policy</strong> - <b>Condition</b>: COVID-19<br/><b>Intervention</b>: Diagnostic Test: Lateral Flow Device<br/><b>Sponsor</b>: University College, London<br/><b>Not yet recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Asunercept for the Treatment of Patients With Moderate to Severe COVID-19 Disease</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Biological: Asunercept; Other: Placebo<br/><b>Sponsor</b>: Apogenix AG<br/><b>Recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Study in Adults to Assess the Safety and Efficacy of Inhaled IBIO123, for Post-exposure Prophylaxis of COVID-19</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Biological: IBIO123; Other: Placebo<br/><b>Sponsor</b>: Immune Biosolutions Inc<br/><b>Not yet recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Feasibility and Usability of COVID-19 Antigen RDTs in Uganda</strong> - <b>Condition</b>: COVID-19 Pandemic<br/><b>Interventions</b>: Diagnostic Test: PMC Sure Status COVID-19 Antigen Test; Diagnostic Test: Acon Flowflex COVID-19 Antigen Home Test<br/><b>Sponsor</b>: PATH<br/><b>Not yet recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19</strong> - <b>Conditions</b>: SARS CoV 2 Infection; COVID-19<br/><b>Interventions</b>: Drug: Bemnifosbuvir (BEM); Drug: Placebo<br/><b>Sponsor</b>: Atea Pharmaceuticals, Inc.<br/><b>Recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Roles of Vitamin D and Microbiome in Children With Post-acute COVID-19 Syndromes (PACS) and Long COVID</strong> - <b>Condition</b>: Post-acute COVID-19 Syndromes<br/><b>Interventions</b>: Other: Vitamin D; Other: Placebo<br/><b>Sponsor</b>: China Medical University Hospital<br/><b>Recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Efficacy of Azvudine and Paxlovid in High-risk Patients With COVID-19: A Prospective Randomized Controlled Trial</strong> - <b>Condition</b>: SARS-CoV-2 Infection<br/><b>Interventions</b>: Drug: Azvudine; Drug: Paxlovid group<br/><b>Sponsors</b>: Southeast University, China; Hohhot First Hospital, Hohhot, Inner Mongolia, China<br/><b>Recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and Children</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Biological: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose; Biological: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose; Biological: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose; Biological: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 1 microgram dose<br/><b>Sponsors</b>: BioNTech SE; Pfizer<br/><b>Not yet recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Evaluation of an Integrative Medicine Outpatient Clinical Setting for Post-COVID-19 Patients</strong> - <b>Conditions</b>: COVID-19; Fatigue<br/><b>Interventions</b>: Behavioral: outpatient clinic with multimodal integrative medicine and naturopathy for post-COVID-19 patients; Other: waiting group<br/><b>Sponsor</b>: Universität Duisburg-Essen<br/><b>Recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Post-COVID-19 Chronic Fatigue Syndrome</strong> - <b>Conditions</b>: Post-COVID-19 Syndrome; Post-COVID Syndrome<br/><b>Intervention</b>: Drug: Synthetic Vitamin B1<br/><b>Sponsors</b>: ClinAmygate; As-Salam Center, Maadi, Cairo, Egypt<br/><b>Not yet recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Biological: ABO1020; Biological: Placebo<br/><b>Sponsor</b>: Suzhou Abogen Biosciences Co., Ltd.<br/><b>Active, not recruiting</b></p></li>
|
||
</ul>
|
||
<h1 data-aos="fade-right" id="from-pubmed">From PubMed</h1>
|
||
<ul>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Dynamics and binding affinity of nucleoside and non-nucleoside inhibitors with RdRp of SARS-CoV-2: a molecular screening, docking, and molecular dynamics simulation study</strong> - No abstract</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Repurposing FDA-approved drugs cetilistat, abiraterone, diiodohydroxyquinoline, bexarotene, and remdesivir as potential inhibitors against RNA dependent RNA polymerase of SARS-CoV-2: A comparative in silico perspective</strong> - No abstract</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Effect of Near-Infrared and blue laser light on Vero E6 cells SARS-CoV-2 infection model</strong> - No abstract</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Upper Respiratory Tract Microbiome Network Impacted by SARS-CoV-2</strong> - No abstract</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Reduced immunogenicity of BNT162b2 booster vaccination in combination with a tetravalent influenza vaccination: results of a prospective cohort study in 838 health workers</strong> - No abstract</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Design, synthesis, and pharmacological evaluations of pyrrolo[1,2-a]quinoxaline-based derivatives as potent and selective sirt6 activators</strong> - No abstract</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Discovery and structural optimization of 3-O-β-Chacotriosyl betulonic acid saponins as potent fusion inhibitors of Omicron virus infections</strong> - No abstract</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Synergism of TNF-α and IFN-β triggers human airway epithelial cells death by apoptosis and pyroptosis</strong> - No abstract</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System : A Population-Based Cohort Study</strong> - No abstract</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Phenotypic screening of 1,953 FDA-approved drugs reveals 26 hits with potential for repurposing for Peyronie’s disease</strong> - No abstract</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The preclinical discovery and development of molnupiravir for the treatment of SARS-CoV-2 (COVID-19)</strong> - No abstract</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Inhibition of glycogen synthase kinase-3-beta (GSK3β) blocks nucleocapsid phosphorylation and SARS-CoV-2 replication</strong> - No abstract</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Antiviral properties of porous graphene, graphene oxide and graphene foam ultrafine fibers against Phi6 bacteriophage</strong> - No abstract</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Enhancing motivation and psychological wellbeing in the workplace through conscious physical activity: Suggestions from a qualitative study examining workers’ experience</strong> - No abstract</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Sequential Treatment by Antiviral Drugs Followed by Immunosuppressive Agents for COVID-19 Patients with Hematological Malignancy</strong> - No abstract</p></li>
|
||
</ul>
|
||
<h1 data-aos="fade-right" id="from-patent-search">From Patent Search</h1>
|
||
|
||
|
||
<script>AOS.init();</script></body></html> |